Background: Reversible vasoconstriction (RV) may cause ischaemic stroke (IS) in the absence of any other defined stroke aetiology. The three objectives of our study were to evaluate the frequency of RV in a prospective series of young IS patients, to describe the detailed clinical-radiological features in the patients with RV and IS, and to compare these characteristics with those of reversible cerebral vasoconstriction syndrome (RCVS). Methods: We identified between October 2005 and December 2010, 159 consecutive young patients (<45 years) hospitalized for an acute IS confirmed by cerebral magnetic resonance imaging. An extensive diagnostic work-up was performed including toxicological urinary screening for cannabis, cocaine and amphetamines, and the usual biological, cardiac and vascular investigations for an IS in the young. We specifically studied patients with IS and RV, which was defined as multifocal intracranial arterial stenoses confirmed by intracranial arterial imaging that resolved within 3-6 months. Results: Out of 159 patients with IS, 21 (13%, 12 males, 9 females; mean age 32 years) had multifocal cerebral arterial stenoses that were fully reversible at 3-6 months, and no other cause for stroke. IS were located on posterior territory in 71% of cases, and vasoconstriction predominated on posterior cerebral and superior cerebellar arteries. Precipitating factors of IS and RV were the use of cannabis resin (n = 14), nasal decongestants (n = 2) and triptan (n = 1). Most cases (74%) had unusual severe headache, but none had thunderclap headache. None of 21 cases had reversible posterior leukoencephalopathy, cortical subarachnoid or intracerebral haemorrhage. Conclusion: RV was the sole identified cause of IS in 13% of our cohort. These young patients with IS and RV may have a variant of RCVS, related to an increased susceptibility to vasoactive agents in some individuals. RV in our patients differs from the classical characteristics of RCVS by the absence of thunderclap headache, reversible brain oedema and subarachnoid or intracranial haemorrhage. Intracranial arteries should be looked for, by appropriate vascular imaging, in young patients with IS at the acute stage and during the follow-up period.

Keywords:
Ischaemic stroke, Young people, Cannabis, Intracranial arterial stenosis, Vasoconstriction, Reversible cerebral vasoconstriction syndrome, Vasoconstriction syndrome
1.
Yamamoto FI: Ischemic stroke in young adults: an overview of etiological aspects. Arq Neuropsiquiatr 2012;70:462-466.
2.
Wolff V, Lauer V, Rouyer O, Sellal F, Meyer N, Raul JS, Sabourdy C, Boujan F, Jahn C, Beaujeux R, Marescaux C: Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke 2011;42:1778-1780.
3.
Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB: Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007;146:34-44.
4.
Sattar A, Manousakis G, Jensen MB: Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther 2010;8:1417-1421.
5.
Chen SP, Fuh JL, Wang SJ: Reversible cerebral vasoconstriction syndrome: current and future perspectives. Expert Rev Neurother 2011;11:1265-1276.
6.
Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, Calabrese LH: Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol 2011;68:1005-1012.
7.
Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG: The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007;130:3091-3101.
8.
Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG: Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke 2010;41:2505-2511.
9.
Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Koroshetz WJ: Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-133.
10.
Chen SP, Fuh JL, Wang SJ, Chang FC, Lirng JF, Fang YC, Shia BC, Wu JC: Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol 2010;67:648-656.
11.
Noda K, Fukae J, Fujishima K, Mori K, Urabe T, Hattori N, Okuma Y: Reversible cerebral vasoconstriction syndrome presenting as subarachnoid hemorrhage, reversible posterior leukoencephalopathy, and cerebral infarction. Intern Med 2011;50:1227-1233.
12.
Chen SP, Fuh JL, Chang FC, Lirng JF, Shia BC, Wang SJ: Transcranial color doppler study for reversible cerebral vasoconstriction syndromes. Ann Neurol 2008;63:751-757.
13.
Mawet J, Boukobza M, Franc J, Sarov M, Arnold M, Bousser MG, Ducros A: Reversible cerebral vasoconstriction syndrome and cervical artery dissection in 20 patients. Neurology 2013;81:821-824.
14.
Robert T, Kawkabani Marchini A, Oumarou G, Uské A: Reversible cerebral vasoconstriction syndrome identification of prognostic factors. Clin Neurol Neurosurg 2013;115:2351-2357.
15.
Ducros A: Reversible cerebral vasoconstriction syndrome. Lancet Neurol 2012;11:906-917.
16.
Ji R, Schwamm LH, Pervez MA, Singhal AB: Ischemic stroke and transient ischemic attack in young adults: risk factors, diagnostic yield, neuroimaging, and thrombolysis. JAMA Neurol 2013;70:51-57.
17.
Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, Kaste M, Tatlisumak T: Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009;40:1195-1203.
18.
Wolff V, Armspach JP, Beaujeux R, Manisor M, Rouyer O, Lauer V, et al: High frequency of intracranial arterial stenoses and cannabis use in ischaemic stroke in the young. Cerebrovasc Dis 2014;37:438-443.
19.
Von Sarnowski B, Schminke U, Tatlisumak T, Putaala J, Grittner U, Kaps M, Tobin WO, Kinsella JA, McCabe DJ, Hennerici MG, Fazekas F, Norrving B, Kessler C, Rolfs A; sifap1 investigators: Prevalence of stenosis and occlusions of brain-supplying arteries in young stroke patients. Neurology 2013;80:1287-1294.
20.
Katz BS, Fugate JE, Ameriso SF, Pujol-Lereis VA, Mandrekar J, Flemming KD, Kallmes DF, Rabinstein AA: Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol 2014;71:68-73.
21.
Cheng YC, Kuo KH, Lai TH: A common cause of sudden and thunderclap headaches: reversible cerebral vasoconstriction syndrome. J Headache Pain 2014;15:13.
22.
O'Sullivan SE, Kendall DA, Randall MD: Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur J Pharmacol 2005;507:211-221.
23.
Kunos G, Jarai Z, Varga K, Liu J, Wang L, Wagner JA: Cardiovascular effects of endocannabinoids - the plot thickens. Prostaglandins Other Lipid Mediat 2000;61:71-84.
24.
Barbosa PP, Lapa AJ, Lima-Landman MT, Valle JR: Vasoconstriction induced by delta 9-tetrahydrocannabinol on the perfused rabbit ear artery. Arch Int Pharmacodyn Ther 1981;252:253-261.
25.
Adams MD, Earnhardt JT, Dewey WL, Harris LS: Vasoconstrictor actions of delta 8- and delta 9-tetrahydrocannabinol in the rat. J Pharmacol Exp Ther 1976;196:649-656.
26.
Wolff V, Armspach JP, Lauer V, Rouyer O, Bataillard M, Marescaux C, Geny B: Cannabis-related stroke: myth or reality? Stroke 2013;44:558-563.
27.
Thomas G, Kloner RA, Rezkalla S: Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014;113:187-190.
28.
Jouanjus E, Lapeyre-Mestre M, Micallef J; French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications: Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014;3:e000638.
29.
Desbois AC, Cacoub P: Cannabis-associated arterial disease. Ann Vasc Surg 2013;27:996-1005.
30.
Chen SP, Fuh JL, Wang SJ, Tsai SJ, Hong CJ, Yang AC: Brain-derived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes. PLoS One 2011;6:e18024.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.